Lexeo Therapeutics (LXEO) Projected to Post Quarterly Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) is expected to be announcing its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.19). On average, analysts expect Lexeo Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO opened at $4.53 on Friday. The stock’s 50-day moving average is $4.17 and its two-hundred day moving average is $3.73. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.42 and a quick ratio of 3.42. Lexeo Therapeutics has a 1-year low of $1.45 and a 1-year high of $12.76. The company has a market cap of $150.40 million, a price-to-earnings ratio of -1.37 and a beta of 1.36.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. dropped their price objective on Lexeo Therapeutics from $16.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, May 30th. Chardan Capital dropped their price objective on Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. HC Wainwright dropped their price objective on Lexeo Therapeutics from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 16th. Finally, Oppenheimer assumed coverage on Lexeo Therapeutics in a report on Thursday, July 31st. They issued an “outperform” rating and a $20.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $17.17.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its stake in Lexeo Therapeutics by 19.8% during the 1st quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after buying an additional 4,995 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Lexeo Therapeutics during the 1st quarter worth approximately $85,000. AQR Capital Management LLC grew its stake in Lexeo Therapeutics by 370.0% during the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after buying an additional 39,627 shares during the last quarter. Finally, Millennium Management LLC grew its stake in Lexeo Therapeutics by 654.8% during the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after buying an additional 929,538 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.